CPH.TO - Cipher Pharmaceuticals Inc.

Toronto - Toronto Delayed Price. Currency in CAD
1.2000
-0.0300 (-2.44%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.2300
Open1.2100
Bid1.2000 x 0
Ask1.2100 x 0
Day's Range1.1800 - 1.2100
52 Week Range1.1100 - 3.6600
Volume8,700
Avg. Volume25,062
Market Cap32.294M
Beta (3Y Monthly)0.61
PE Ratio (TTM)12.63
EPS (TTM)0.0950
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.87
  • Do You Know What Cipher Pharmaceuticals Inc.'s (TSE:CPH) P/E Ratio Means?
    Simply Wall St.15 days ago

    Do You Know What Cipher Pharmaceuticals Inc.'s (TSE:CPH) P/E Ratio Means?

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...

  • GlobeNewswirelast month

    Cipher Pharmaceuticals Reports Voting Results for the Election of Directors

    Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on June 11, 2019 in Toronto, Ontario. A total of 16,185,291 common shares representing 60.12% of the Company's issued and outstanding common shares as of the record date for the meeting, were represented by shareholders present in person and by proxy at the meeting.

  • A Look At The Fair Value Of Cipher Pharmaceuticals Inc. (TSE:CPH)
    Simply Wall St.last month

    A Look At The Fair Value Of Cipher Pharmaceuticals Inc. (TSE:CPH)

    In this article we are going to estimate the intrinsic value of Cipher Pharmaceuticals Inc. (TSE:CPH) by projecting...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CPH.TO earnings conference call or presentation 10-May-19 12:30pm GMT

    Q1 2019 Cipher Pharmaceuticals Inc Earnings Call

  • Should Cipher Pharmaceuticals Inc. (TSE:CPH) Focus On Improving This Fundamental Metric?
    Simply Wall St.2 months ago

    Should Cipher Pharmaceuticals Inc. (TSE:CPH) Focus On Improving This Fundamental Metric?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • CNW Group2 months ago

    Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

    OAKVILLE, ON , May 10, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31 st, 2019. The Company continues to execute on its corporate strategy focusing on long-term growth. Utilizing cash flows from its profitable global licensing business, Cipher is building a diversified portfolio of prescription products with near term value catalysts.

  • CNW Group3 months ago

    Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

    Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

  • How Financially Strong Is Cipher Pharmaceuticals Inc. (TSE:CPH)?
    Simply Wall St.3 months ago

    How Financially Strong Is Cipher Pharmaceuticals Inc. (TSE:CPH)?

    Investors are always looking for growth in small-cap stocks like Cipher Pharmaceuticals Inc. (TSE:CPH), with a market cap of CA$34m. However, an important fact which most ignore is: how financially healthy is the business...

  • CNW Group4 months ago

    Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors

    OAKVILLE, ON , March 26, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately. Mr. Craig Mull is the managing director of 1207407 Ontario Limited and is responsible for overseeing a variety of investments including the company's shareholding in Cipher. Mr. Mull is also the founder and CEO of the Typhon Group Ltd., a privately held real estate development firm which owns and develops commercial and residential projects throughout the Greater Toronto Area .

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CPH.TO earnings conference call or presentation 19-Mar-19 12:30pm GMT

    Q4 2018 Cipher Pharmaceuticals Inc Earnings Call

  • CNW Group4 months ago

    Cipher Pharmaceuticals Announces Change to Management Team

    OAKVILLE, ON , March 20, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced that Stephen Lemieux , Chief Financial Officer and Secretary of Cipher has resigned to pursue other career opportunities. Mr. Lemieux will leave the Company on March 29, 2019 . Mr. Lemieux has agreed to a consulting agreement with the Company to assist in the orderly transition of his responsibilities.

  • CNW Group4 months ago

    Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

    Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

  • Before You Buy Cipher Pharmaceuticals Inc. (TSE:CPH), Consider Its Volatility
    Simply Wall St.5 months ago

    Before You Buy Cipher Pharmaceuticals Inc. (TSE:CPH), Consider Its Volatility

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching Cipher Pharmaceuticals Inc. (TSE:CPH) mightRead More...

  • Does Cipher Pharmaceuticals Inc. (TSE:CPH) Have A Good P/E Ratio?
    Simply Wall St.6 months ago

    Does Cipher Pharmaceuticals Inc. (TSE:CPH) Have A Good P/E Ratio?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We'll look at Cipher Pharmaceuticals Inc.'s (TSE:CPH) P/E ratio and reflect Read More...

  • ACCESSWIRE6 months ago

    Today's Research Reports on CardioComm Solutions, Cipher Pharmaceuticals, Medicure and Aphria

    NEW YORK, NY / ACCESSWIRE / January 17, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • How Much Of Cipher Pharmaceuticals Inc. (TSE:CPH) Do Insiders Own?
    Simply Wall St.6 months ago

    How Much Of Cipher Pharmaceuticals Inc. (TSE:CPH) Do Insiders Own?

    If you want to know who really controls Cipher Pharmaceuticals Inc. (TSE:CPH), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, Read More...

  • CNW Group7 months ago

    Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada

    MISSISSAUGA, ON , Dec. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada. Cipher acquired the exclusive Canadian rights to distribute and commercialize A-101 40% from Aclaris Therapeutics, Inc. (ACRS) ("Aclaris") in April 2018 . A-101 40% is a U.S. Food and Drug Administration ("FDA")-approved product indicated for the treatment of raised SKs, which are commonly occurring non-cancerous skin growths that affect more than 9 million Canadian adults and can be an aesthetic skin concern.

  • CNW Group7 months ago

    Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

    MISSISSAUGA, ON , Dec. 17, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) today  announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") in February 2018 . It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months1.

  • Simply Wall St.7 months ago

    What Should We Expect From Cipher Pharmaceuticals Inc.’s (TSE:CPH) Earnings Over The Next Year?

    Looking at Cipher Pharmaceuticals Inc.'s (TSE:CPH) earnings update in September 2018, analysts seem cautiously optimistic, as a 30% increase in profits is expected in the upcoming year, relative to the Read More...

  • CNW Group8 months ago

    Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018

    MISSISSAUGA, ON , Dec. 5, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET . During the webcast, Robert Tessarolo , President and CEO will provide an introductory presentation through a PowerPoint discussion that will cover key areas of Cipher's business. During parts of the presentation, investors will have an opportunity to ask relevant questions and interact with management through an interactive Q and A portal. An archived version of the webcast and presentation will be available on the Investors section of the Company's website http://www.cipherpharma.com/ following the event.

  • CNW Group8 months ago

    Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations

    MISSISSAUGA, ON, Dec. 4, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced that pharmaceutical industry commercial executive, Michael Milloy , has joined the Company in the position of Vice President, Canadian Commercial Operations. Prior to joining Cipher, Mr. Milloy, held the position of Business Unit Head, Neurology & Immunology with EMD Serono, where he was responsible for the executive leadership and strategic direction to a business unit growing at an annual growth rate of 30%.

  • ACCESSWIRE8 months ago

    Today's Research Reports on Aurinia Pharmaceuticals, Trillium Therapeutics, Cipher Pharmaceuticals and Helius Medical Technologies

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • Zacks Small Cap Research8 months ago

    CORV: Topline Growth Accelerating

    Loss per share was ($0.20) as SG&A expenses grew reflecting an increase in the sales force. Newsflow during the third quarter continued to be very positive for Brinavess, and management has guided to a 2Q:19 resubmission to the FDA. Trevyent is now in the hands of United Therapeutics (UTHR) following their acquisition of SteadyMed.

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of CPH.TO earnings conference call or presentation 7-Nov-18 1:30pm GMT

    Q3 2018 Cipher Pharmaceuticals Inc Earnings Call

  • CNW Group8 months ago

    Cipher Pharmaceuticals Reports Q3 2018 Results

    MISSISSAUGA, ON , Nov. 7, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced its financial and operating results for the three and nine months ended September 30 th, 2018. The Company continues to execute on its revised corporate strategy focusing on long term growth that was introduced last year by the new management team. Utilizing strong cash flows from its profitable global licensing business, the Company continues to invest in and build a diversified portfolio of prescription products across a broad range of therapeutic areas that meet unmet medical needs.